NCT06062823View on ClinicalTrials.gov

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

PHASE2RecruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions

NSCLC

Interventions

DRUG

Afatinib 40 MG

Afatinib 40mg administered orally daily.

Trial Locations (1)

Unknown

RECRUITING

National University Hospital, Singapore

All Listed Sponsors

lead

National University Hospital, Singapore

OTHER